PIP 2
Alternative Names: PIP-2Latest Information Update: 28 Feb 2024
At a glance
- Originator University of Pennsylvania
- Developer Peroxitech
- Class Anti-inflammatories; Peptides
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Intraperitoneal)
- 13 Dec 2022 Peroxitech plans a clinical trial for Acute lung injury in
- 12 May 2021 Peroxitech Therapeutics plans pharmacokinetics and toxicology preclinical trial for Acute lung injury